Role of inflammation in Atrial fibrillation pathophysiology and management

Circulation Journal

Volumn 79, Issue 3, 2015, Pages 495-502

  Harada, Masahide ^a   Van Wagoner, David R ^b   Nattel, Stanley ^c  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Anti inflammatory drugs; Atrial fibrillation; Inflammatory markers; Thrombogenesis

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN II; ASCORBIC ACID; C REACTIVE PROTEIN; CD40 LIGAND; COLCHICINE; GELATINASE A; GROWTH DIFFERENTIATION FACTOR 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; MICRORNA; MICRORNA 26; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; P SELECTIN GLYCOPROTEIN LIGAND 1; POLYUNSATURATED FATTY ACID; PREDNISONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; AUTACOID; BIOLOGICAL MARKER;

APOPTOSIS; BLOOD CLOTTING; CALCIUM SIGNALING; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBROSIS; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; ANIMAL; ATRIAL FIBRILLATION; BLOOD; PATHOLOGY;

ANIMALS; APOPTOSIS; ATRIAL FIBRILLATION; BIOMARKERS; BLOOD COAGULATION; FIBROSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OXIDATIVE STRESS;

EID: 84923465521     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0138     Document Type: Review

References (77)

1. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Col Cardiol 2012; 60: 2263–2270.
2. Vilchez JA, Roldan V, Hernandez-Romero D, Valdes M, Lip GY, Marin F. Biomarkers in atrial fibrillation: An overview. Int J Clin Pract 2014; 68: 434–443.
3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180–1184.
4. Maesen B, Maessen JN, Allessie M, Schotten U. Post-operative atrial fibrillation: A maze of mechanisms. Europace 2012; 14: 159–174.
5. Hofmann U, Frantz S. How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res Cardiol 2013; 108: 356.
6. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114: 1867–1879.
7. Duchatelle V, Kritikou EA, Tardif JC. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Can J Cardiol 2012; 28: 678–686.
8. Schiffrin EL. The immune system: Role in hypertension. Can J Cardiol 2013; 29: 543–548.
9. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation relationship among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114: 1453–1468.
10. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: Role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008; 52: 306–313.
11. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155–166.
12. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JRB, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology. PLoS One 2014; 9: e99495, doi:10.1371/journal.pone.0099495.
13. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study. Am Heart J 2008; 155: 303–309.
14. Kristensen SL, Lindhardsen J, Ahlehoff O, Lamberts M, Khalid U, Torp-pedersen C, et al. Increased risk of atrial fibrillation and stroke during active stage of inflammatory bowel disease: A nationwide study. Europace 2014; 16: 477–484.
15. Chen MC, Chang JP, Liu WH, Yang CH, Chen YL, Tsai TH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol 2008; 102: 861–865.
16. Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16: 470–474.
17. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262–270.
18. Liao C, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010; 120: 242–253.
19. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, et al. Oxidative stress in atrial fibrillation: An emerging role of NADPH oxidase. J Mol Cell Cardiol 2013; 62: 72–79.
20. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: Mechanisms and implications. J Am Coll Cardiol 2014; 63: 2335–2345.
21. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart: To be or not to be NF-κB. Circ Res 2011; 108: 1122–1132.
22. Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM, et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J 2013; 77: 1171–1179.
23. Cao H, Wang J, Xi L, Roe OD, Chen Y, Wang D. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. Circ J 2011; 75: 2781–2788.
24. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, et al. NF-κBdependent transcriptional regulation of the cardiac SCN5a sodium channel by angiotensin. Am J Physiol Cell Physiol 2008; 294: C372–C379.
25. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Cames CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886–2891.
26. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk?: A Mendelian randomization of 47000 individuals from the general population. J Am Coll Cardiol 2010; 56: 789–795.
27. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. Highsensitive C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108: 346–353.
28. Wu N, Xiang Y, Wu L, Zhang Y, Ma X, Tong S, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol 2013; 169: 62–72.
29. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin- 6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 148: 462–466.
30. Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation. Am J Cardiol 2012; 109: 95–99.
31. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462–466.
32. Roldan V, Marin F, Diaz J, Gallego P, Jover E, Romera M, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012; 10: 1500–1507.
33. Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhawar N, et al. Intra and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010; 7: 149–154.
34. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. The role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438–444.
35. Pinto A, Tuttolomondo A, Casuccio A, Raimondo DD, Sciacca RD, Arnao V, et al. Immuno-inflammatory predictors of stroke at followup in patients with chronic non-valvular atrial fibrillation. Clin Sci 2009; 116: 781–789.
36. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jonsson A, Safstrom K, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008; 10: 848–853.
37. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, et al. The predictive value of inflammatory and oxydative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009; 135: 361–369.
38. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 130: 1847–1858.
39. Izumiya Y, Hanatani S, Kimura Y, Yamamoto E, Kusaka H, Tokitsu T, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338–344.
40. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802–809.
41. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43: 292–297.
42. Sonmez O, Ertem FU, Vatankulu MA, Erdogan E, Tasal A, Kucukbuzcu S, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med Sci Monit 2014; 20: 463–470.
43. Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M, et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011; 22: 987–993.
44. Ito K, Date T, Ikegami M, Hongo K, Fujisaki M, Katoh D, et al. An immunohistochemical analysis of tissue thrombin expression in the human atria. PLoS One 2013; 8: e65817, doi:10.1371/journal.pone.0065817.
45. Jacob KA, Nathoe HM, Deleman JM, Osch DV, Kluin J, Dijik DV. Inflammation in new-onset atrial fibrillation after cardiac surgery: A systematic review. Eur J Clin Invest 2014; 44: 402–428.
46. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation-promotion by atrial tachycardia remodeling in dogs. Circulation 2004; 110: 2313–2319.
47. Pena JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33: 531–537.
48. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al. Effect of statins on atrial fibrillation: Collaborative metaanalysis of published and unpublished evidence from randomized controlled trials. BMJ 2011; 342: d11250.
49. Bang CN, Greve AM, Abdulla J, Kober L, Gislason GH, Wachtell K. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis. Int J Cardiol 2013; 167: 624–630.
50. Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: A double-blind, placebocontrolled, randomized trial. Heart Rhythm 2012; 9: 172–178.
51. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006; 69: 865–875.
52. Ho KM, Tan JA. Benefits and risk of corticosteroid prophylaxis in adult cardiac surgery: A dose-response meta-analysis. Circulation 2009; 119: 1853–1866.
53. Baker WL, White CM, Kluger J, Denowitz A, Konecny CP, Coleman CL. Effect of perioperative corticosteroids use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm 2007; 4: 461–468.
54. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamazaki H, Kuroki K, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation. J Am Col Cardiol 2010; 56: 1463–1472.
55. Won H, Kim JY, Shim J, Uhm JS, Pak HN, Lee MH, et al. Effect of a single bolus injection of low-dose hydrocortisone for prevention of atrial fibrillation recurrence after radiofrequency catheter ablation. Circ J 2013; 77: 53–59.
56. Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community: The Shibata study. Stroke 2000; 31: 2287–2294.
57. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001; 89: E32–E38.
58. Harling L, Rasoli S, Vecht JA, Ashrafian H, Kourliouros A, Athanasiou T. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011; 97: 1636–1642.
59. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, et al. A randomized controlled trial to prevent postoperative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013; 62: 1457–1465.
60. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005; 102: 321–326.
61. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007; 116: 2101–2109.
62. Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al; AFFORD Investigators. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. J Am Coll Cardiol 2014; 64: 1441–1448.
63. Mozaffarian D, Wu JH, de Oliveira Otto MC, Sandesara CM, Metcalf RG, Latini R, et al. Fish oil and post-operative atrial fibrillation: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2013; 61: 2194–2196.
64. Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, et al; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011; 124: 2290–2295.
65. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: The COPPS-2 randomized clinical trial. JAMA 2014; 312: 1016–1023.
66. Thambidorai SK, Parakh K, Martin DO. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805–807.
67. Cianfrocca C, Loricchio ML, Pelliccia F, Pasceri V, Auriti A, Bianconi L, et al. C-reactive protein and left atrial appendage velocity are independent determinants of the risk of thrombogenesis in patients with atrial fibrillation. Int J Cardiol 2010; 142: 22–28.
68. Shin SY, Na JO, Lim HE, Choi CU, Choi JI, Kim SH, et al. Improved endothelial function in patients with atrial fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc Electrophysiol 2011; 22: 376–382.
69. Tousoulis D, Zisimos K, Antoniades C, Stefanadi E, Siasos G, Tsioufis C, et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distention. Int J Cardiol 2009; 136: 258–262.
70. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, et al. High von Willebrand factor levels increase the risk of stroke: The Rotterdam study. Stroke 2010; 41: 2151–2156.
71. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, et al. Atrial fibrillation and the prothrombotic state in the elderly: The Rotterdam Study. Stroke 2003; 34: 413–417.
72. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: Impact of rate and rhythm. J Am Coll Cardiol 2013; 61: 852–860.
73. Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: Involvement of mononuclear cellplatelet interaction. Thromb Res 2011; 128: e113–e118, doi:10.1016/j.thromres.2011.07.013.
74. Lim HS, Willoughby SR, Schultz C, Chakrabarty A, Alasady M, Lau DH, et al. Successful catheter ablation decreases platelet activation and improves endothelial function in patients with atrial fibrillation. Heart Rhythm 2014; 11: 1912–1918.
75. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513–520.
76. Neumann FJ, Ott I, Matx N, Luther T, Gawaz M, Kotzsch M, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17: 3399–3405.
77. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43: 331–340.